5.83
price down icon4.27%   -0.26
after-market After Hours: 5.83
loading
Lipocine Inc stock is traded at $5.83, with a volume of 38,419. It is down -4.27% in the last 24 hours and up +25.11% over the past month. Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$6.09
Open:
$6.08
24h Volume:
38,419
Relative Volume:
1.21
Market Cap:
$31.39M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-2.4496
EPS:
-2.38
Net Cash Flow:
$-11.88M
1W Performance:
+4.67%
1M Performance:
+25.11%
6M Performance:
+24.57%
1Y Performance:
+125.97%
1-Day Range:
Value
$5.36
$6.08
1-Week Range:
Value
$5.36
$6.1683
52-Week Range:
Value
$2.35
$11.79

Lipocine Inc Stock (LPCN) Company Profile

Name
Name
Lipocine Inc
Name
Phone
801 994 7383
Name
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Name
Employee
17
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
LPCN's Discussions on Twitter

Lipocine Inc Stock (LPCN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-24-21 Initiated Cantor Fitzgerald Overweight
Dec-10-20 Upgrade Ladenburg Thalmann Neutral → Buy
Jan-12-18 Reiterated H.C. Wainwright Buy
Jan-11-18 Downgrade Canaccord Genuity Buy → Hold
Dec-08-17 Resumed H.C. Wainwright Buy
Oct-07-16 Initiated H.C. Wainwright Buy
Jul-22-15 Initiated ROTH Capital Buy
Jun-23-15 Initiated Canaccord Genuity Buy
View All

Lipocine Inc Stock (LPCN) Latest News

pulisher
Nov 04, 2024

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - GuruFocus.com

Nov 04, 2024
pulisher
Oct 31, 2024

Lipocine inks deal to bring TLANDO to South Korea - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Lipocine Partners With SPC Korea For TLANDO In South Korea - Contract Pharma

Oct 31, 2024
pulisher
Oct 31, 2024

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - Marketscreener.com

Oct 31, 2024
pulisher
Oct 30, 2024

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study i - GuruFocus.com

Oct 30, 2024
pulisher
Oct 28, 2024

Trading (LPCN) With Integrated Risk Controls - Stock Traders Daily

Oct 28, 2024
pulisher
Oct 28, 2024

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1 - GuruFocus.com

Oct 28, 2024
pulisher
Oct 25, 2024

Lipocine Announces Completion of Dosing in Pivotal Study of Post - GuruFocus.com

Oct 25, 2024
pulisher
Oct 18, 2024

(LPCN) Trading Signals - Stock Traders Daily

Oct 18, 2024
pulisher
Oct 11, 2024

Lipocine reports promising oral brexanolone study results By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 11, 2024

Lipocine reports promising oral brexanolone study results - Investing.com India

Oct 11, 2024
pulisher
Oct 10, 2024

Lipocine Enters Exclusive Supply And Distribution Agreement With Pharmalink - Contract Pharma

Oct 10, 2024
pulisher
Oct 10, 2024

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results - PR Newswire

Oct 10, 2024
pulisher
Oct 09, 2024

Lipocine signs supply and distribution agreement with Pharmalink for Tlando - Yahoo Finance

Oct 09, 2024
pulisher
Oct 08, 2024

Lipocine partners with Pharmalink for GCC distribution of TLANDO - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Lipocine partners with Pharmalink for GCC distribution of TLANDO By Investing.com - Investing.com Nigeria

Oct 08, 2024
pulisher
Oct 08, 2024

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PR Newswire

Oct 08, 2024
pulisher
Oct 08, 2024

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO in the Gulf Cooperation Council Countries - Marketscreener.com

Oct 08, 2024
pulisher
Oct 02, 2024

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Citizentribune

Oct 02, 2024
pulisher
Sep 24, 2024

Alliance Global Partners Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World

Sep 24, 2024
pulisher
Sep 21, 2024

Lipocine (NASDAQ:LPCN) Upgraded to Buy at StockNews.com - Defense World

Sep 21, 2024
pulisher
Sep 18, 2024

‘Lubber Pandhu also has strong emotions beyond cricket’ - DTNEXT

Sep 18, 2024
pulisher
Sep 18, 2024

Louisiana-Pacific director sells $245,750 in company stock By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 18, 2024

PLRX’s 52-Week Rollercoaster: From $10.29 to $19.62 – What’s Next for Investors? - The InvestChronicle

Sep 18, 2024
pulisher
Sep 17, 2024

Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees - Stockhead

Sep 17, 2024
pulisher
Sep 17, 2024

Pliant Therapeutics (NASDAQ:PLRX) Sees Large Volume Increase - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

Liquidia Corp [LQDA] Investment Guide: What You Need to Know - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

MediPharm Labs Corp. - Baystreet.ca

Sep 17, 2024
pulisher
Sep 17, 2024

A stock that deserves closer examination: Lipella Pharmaceuticals Inc (LIPO) - US Post News

Sep 17, 2024
pulisher
Sep 16, 2024

PLRX’s latest rating updates from top analysts. - Knox Daily

Sep 16, 2024
pulisher
Sep 16, 2024

Labcorp Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 16, 2024
pulisher
Sep 16, 2024

Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00 - MarketBeat

Sep 16, 2024
pulisher
Sep 14, 2024

Prudential PLC Sells 7,956 Shares of Laboratory Co. of America Holdings (NYSE:LH) - MarketBeat

Sep 14, 2024
pulisher
Sep 14, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Sep 14, 2024
pulisher
Sep 12, 2024

Research Analysts Set Expectations for Pliant Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:PLRX) - Defense World

Sep 12, 2024
pulisher
Sep 05, 2024

Lipocine Inc. filed SEC Form 8-K: Financial Statements and Exhibits - Quantisnow

Sep 05, 2024
pulisher
Sep 05, 2024

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® - Kilgore News Herald

Sep 05, 2024
pulisher
Aug 30, 2024

Lipocine (NASDAQ:LPCN) Downgraded by StockNews.com to “Hold” - Defense World

Aug 30, 2024
pulisher
Aug 27, 2024

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference – Company Announcement - Financial Times

Aug 27, 2024
pulisher
Aug 27, 2024

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Aug 27, 2024
pulisher
Aug 22, 2024

Sarcopenia Market to Grow Positively at a Paltry CAGR During - openPR

Aug 22, 2024
pulisher
Aug 17, 2024

StockNews.com Lowers Lipocine (NASDAQ:LPCN) to Hold - Defense World

Aug 17, 2024
pulisher
Aug 12, 2024

Lipocine (NASDAQ:LPCN) Raised to Buy at StockNews.com - Defense World

Aug 12, 2024
pulisher
Aug 09, 2024

Lipocine: Q2 Earnings Snapshot - San Antonio Express-News

Aug 09, 2024
pulisher
Aug 08, 2024

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024 - Manchestertimes

Aug 08, 2024
pulisher
Aug 08, 2024

LPCNLipocine Inc. Latest Stock News & Market Updates - StockTitan

Aug 08, 2024
pulisher
Aug 08, 2024

Lipocine (NASDAQ:LPCN) Stock Price Passes Below Two Hundred Day Moving Average of $5.52 - Defense World

Aug 08, 2024
pulisher
Aug 03, 2024

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 - Quantisnow

Aug 03, 2024
pulisher
Aug 02, 2024

Lipocine to Present at 36th Annual Roth Conference - Quantisnow

Aug 02, 2024
pulisher
Jul 31, 2024

Lipocine (NASDAQ:LPCN) Stock Crosses Below Two Hundred Day Moving Average of $5.48 - Defense World

Jul 31, 2024
pulisher
Jul 27, 2024

Trend Tracker for (LPCN) - Stock Traders Daily

Jul 27, 2024

Lipocine Inc Stock (LPCN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):